https://techcrunch.com/2020/04/24/fda-reiterates-risks-of-antimalarial-drug-use-for-covid-19-as-study-into-efficacy-ends-early-due-to-deaths/

The U.S. Food and Drug Administration (FDA) has issued a new warning about the known side effects of hydroxychrloroquine and chloroquine, two antimalarial drugs (also used in the treatment of chronic rheumatoid arthritis and lupus), on the same day that a group of researchers published a paper in the Journal of the American Medical Association about their termination of a study investigating the potential of chloroquine as a potential COVID-19 treatment.

The drugs can have dangerous side-effects, and the study written about in the AMA journal was ended early because the “primary outcome” was the death of study participants, with 22 deaths resulting. Before it was abruptly ended, the researchers found a lethality rate of 39 percent in the group of its subjects who took high dosages, and 15 percent in the low dosage group, with an overall lethality rate of 27 percent.